Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.53 |
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.46 |
| ▸ | MEN1 | O00255 | 9/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7736239 | 1.00 | MAPT (0.53) | MAPTGAANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL1726924 | 1.00 | MAPT (0.53) | MAPTGAANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL922010 | 0.78 | MAPT (0.62) | MAPTGAANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL5780462 | 0.77 | NPC1 (0.49) | MAPTGAANPSR1KDM4ERAB9A | |
| SCHEMBL5780459 | 0.77 | NPC1 (0.55) | MAPTGAANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL5780457 | 0.77 | NPC1 (0.55) | MAPTGAANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL922712 | 0.75 | MAPT (0.81) | MAPTGAANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL922713 | 0.75 | MAPT (0.81) | MAPTGAANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL1767622 | 0.74 | MAPT (0.54) | MAPTGAANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL17769562 | 0.74 | MAPT (0.54) | MAPTGAANPSR1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163088-A1 | COMPOUNDS, COMPOSITION, METHODS, TARGETS FOR CANCER THERAPY | YU MING (US) | 2014-06-12 | — | — | US | claimed |
| US-20110142815-A1 | COMPOUNDS, COMPOSITION, METHODS, TARGETS FOR CANCER THERAPY | YU MING | 2011-06-16 | — | — | US | claimed |
| EP-3936608-B1 | REPROGRAMMING CELLS | SCRIPPS RESEARCH INST (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-3936608-A1 | REPROGRAMMING CELLS | The Scripps Research Institute (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3199623-B1 | REPROGRAMMING CELLS | SCRIPPS RESEARCH INST (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20210095257-A1 | REPROGRAMMING CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2021-04-01 | — | — | US | disclosed |
| US-10738281-B2 | Reprogramming cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190203182-A1 | REPROGRAMMING CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2019-07-04 | — | — | US | disclosed |
| US-20170283776-A1 | REPROGRAMMING CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2017-10-05 | — | — | US | disclosed |
| EP-3199623-A1 | REPROGRAMMING CELLS | The Scripps Research Institute (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9657274-B2 | Reprogramming cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| US-9315779-B2 | Reprogramming cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-04-19 | — | — | US | disclosed |
| US-20140163088-A1 | COMPOUNDS, COMPOSITION, METHODS, TARGETS FOR CANCER THERAPY | YU MING (US) | 2014-06-12 | — | — | US | disclosed |
| US-8680129-B2 | Compounds, composition, methods, targets for cancer therapy | YU MING (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130323833-A1 | REPROGRAMMING CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2013-12-05 | — | — | US | disclosed |
| EP-2553086-A1 | REPROGRAMMING CELLS | The Scripps Research Institute (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-2403497-A1 | COMPOUNDS, COMPOSITIONS AND USE FOR ANTICANCER THERAPY | Yu, Ming (CN) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011123572-A1 | REPROGRAMMING CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110142815-A1 | COMPOUNDS, COMPOSITION, METHODS, TARGETS FOR CANCER THERAPY | YU MING | 2011-06-16 | — | — | US | disclosed |
| WO-2010099731-A1 | COMPOUNDS, COMPOSITIONS AND USE FOR ANTICANCER THERAPY | YU MING (CN) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163088-A1 | COMPOUNDS, COMPOSITION, METHODS, TARGETS FOR CANCER THERAPY | DDIT3, MCL1, BAX | MAPT 2842/4885GAA 3405/4885NPSR1 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.